Results 51 to 60 of about 3,235 (226)

Tezepelumab in severe asthma: a profile of its use

, 2023
   Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Yahiya Y. Syed (4897507)
core   +1 more source

Tezepelumab in Adults with Uncontrolled Asthma

New England Journal of Medicine, 2017
In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose ...
Jonathan, Corren, Jane R, Parnes, Liangwei, Wang, May, Mo, Stephanie L, Roseti, Janet M, Griffiths, René, van der Merwe   +6 more
openaire   +2 more sources

[Tezepelumab: a new option for the treatment of severe asthma]

Revista medica del Instituto Mexicano del Seguro Social, 2023
Resumen En Latinoamérica, el asma es un problema de salud pública con un impacto importante tanto para los pacientes como para los sistemas de salud. El mayor entendimiento de la fisiopatología y el reconocimiento del papel central que tiene la inflamación en la severidad del asma ha favorecido el desarrollo de anticuerpos monoclonales que tienen como ...
Maldonado-Ríos, Valente Armando, Ardila-Herrera, Juan Camilo, Galicia-Sánchez, Luz María, Celis-Preciado, Carlos Andrés   +3 more
openaire   +3 more sources

Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma

Allergy. European Journal of Allergy and Clinical Immunology
Tezepelumab is an anti‐TSLP monoclonal antibody approved for the treatment of severe asthma. It has broad downstream anti‐T2 effects, offering the prospect of biological remission.
Jessica Gates, Faizan Haris, F. Cefaloni, P. Khooshemehri, L. Green, M. Fernandes, L. Thomson, C. Roxas, J. Lam, G. D'ancona, A. Nanzer, J. Dhariwal, D. J. Jackson   +12 more
semanticscholar   +1 more source

Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma

, 2021
Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism.
Yao, Y., Thomsen, S. F., Thomsen, S.F., Ali, Z.   +3 more
core   +1 more source

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study

Journal of Asthma and Allergy, 2021
Jonathan Corren,1 Martin Karpefors,2 Åsa Hellqvist,3 Jane R Parnes,4 Gene Colice5 1Departments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; 2Data Science and AI, AstraZeneca ...
Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G   +4 more
doaj  

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?

Respiratory Research, 2020
Despite treatment with standard-of-care medications, including currently available biologic therapies, many patients with severe asthma have uncontrolled disease, which is associated with a high risk of hospitalization and high healthcare costs. Biologic
Andrew Menzies-Gow, Michael E. Wechsler, Chris E. Brightling   +2 more
doaj   +1 more source

Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials

American Journal of Respiratory and Critical Care Medicine, 2023
Rationale Tezepelumab reduced exacerbations in patients with severe, uncontrolled asthma across a range of baseline blood eosinophil counts and fractional exhaled nitric oxide levels, and irrespective of allergy status, in the phase 2b PATHWAY (Study to ...
J. Corren, A. Menzies-Gow, Geoffrey Chupp, E. Israel, S. Korn, B. Cook, C. Ambrose, A. Hellqvist, S. Roseti, N. Molfino, J. Llanos, N. Martin, K. Bowen, J. Griffiths, J. Parnes, G. Colice   +15 more
semanticscholar   +1 more source

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study

Journal of Asthma and Allergy, 2021
Claire Emson,1 Jonathan Corren,2 Kinga Sałapa,3 Åsa Hellqvist,4 Jane R Parnes,5 Gene Colice6 1Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca ...
Emson C, Corren J, Sałapa K, Hellqvist Å, Parnes JR, Colice G   +5 more
doaj  

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Respiratory Research, 2020
Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologics and ...
Andrew Menzies-Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist, Sandhia Ponnarambil, Primal Kaur, Gennaro Ruberto, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil   +10 more
doaj   +1 more source